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Background: Validated algorithms for identifying progression to metastatic cancer 
could permit the use of administrative claims databases for research in this area.
Objective: To identify simple algorithms that could accurately detect cancer progression 
to metastatic breast, non-small cell lung, and colorectal cancer (CRC) using medical and 
pharmacy claims data.
Methods: Adults with stage I–III breast, non-small cell lung cancer (NSCLC), or CRC 
in the Geisinger Health System from 2004 to 2011 were selected. Evidence of progres-
sion was extracted via manual chart review as the reference standard. In addition to 
secondary malignancy diagnosis (ICD-9 code for metastases), diagnoses, procedures, 
and treatments were selected with clinician input as indicators of cancer progression. 
Random forests models provided variable importance scores. In addition to codes for 
secondary malignancy, several more complex algorithms were constructed and perfor-
mance measures calculated.
results: Among those with breast cancer [17/502 (3.4%) progressed], the perfor-
mance of a secondary malignancy code was suboptimal [sensitivity: 64.7%; specificity: 
86.0%; positive predictive value (PPV): 13.9; negative predictive value (NPV): 98.6%]; 
requiring malignancy at another site or initiation of immunotherapy increased PPV and 
specificity but decreased sensitivity. For NSCLC [61/236 (25.8%) progressed], codes for 
secondary malignancy alone (PPV: 47.4%; NPV: 84.8%; sensitivity: 60.7%; specificity: 
76.6%) performed similarly or better than more complex algorithms. For CRC [33/276 
(12.0%) progressed], secondary malignancy codes had good specificity (92.7%) and 
NPV (92.3%) but low sensitivity (42.4%) and PPV (43.8%); an algorithm with change in 
chemotherapy increased sensitivity but decreased other metrics.
conclusion: Selected algorithms performed similarly to the presence of a secondary 
tumor diagnosis code, with low sensitivity/PPV and higher specificity/NPV. Accurate 
identification of cancer progression likely requires verification through chart review.
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inTrODUcTiOn
Cancer progression is an important outcome in oncology 
research. Administrative claims databases, which are frequently 
used for retrospective studies of treatment patterns, safety, 
and effectiveness of cancer therapies, have no data that can 
directly indicate cancer progression. Metastatic cancer is to 
some extent identifiable through secondary tumor International 
Classification of Diseases, Ninth Revision (ICD-9) codes, but 
the accuracy and completeness of these codes in claims data are 
known to be poor (1).
Numerous algorithms have been published that identify inci-
dent breast, lung, and colorectal cancers (CRCs) (2–10). However, 
identifying metastatic cancer has proven more challenging than 
identifying incident cancers. One study using linked surveillance, 
epidemiology, and end results (SEER) and Medicare data found 
good positive predictive value (PPV) for identifying incident 
breast cancer overall but demonstrated fairly low sensitivity 
(51%) in the subset of patients with stage IV cancer (5); similar 
findings of good specificity but low sensitivity were reported in a 
recent claims database study identifying metastatic breast, lung, 
and CRC (11). Another study used logistic regression modeling 
with the SEER–Medicare data to predict stage IV breast cancer; 
this model achieved reasonable sensitivity (81%) and specificity 
(89%) but had poor PPV (24%) (8). The identification of progres-
sion to metastatic cancer is even more complex than identifying 
metastatic cancer, as data are required on both the change from 
the initial stage at diagnosis to metastasis and the timing of this 
change.
Chubak et al. developed algorithms to identify second breast 
cancer events (recurrence or second primary breast cancer) 
among women enrolled in an integrated health-care system from 
1993 to 2006 (12). One algorithm had high specificity (99%) but 
lower sensitivity (89%) and PPV (90%); a different algorithm 
achieved a higher sensitivity (96%), but lower specificity (95%) 
and PPV (74%). A study of patients in the Kaiser Permanente 
Southern California Health System used a SAS-based coding, 
extraction, and nomenclature tool to identify primary and 
recurrent breast and prostate cancers from pathology reports 
(13). The sensitivity, specificity, and PPV of this tool exceeded 
94% for both cancer types. McClish and colleagues merged 
Medicare inpatient and Part B data with cancer registry data 
and used a logistic regression model to identify predictors of 
recurrent cancer (14). In this study, predictors of cancer recur-
rence included regional or distant stage disease, diagnosis of 
secondary malignancy, and an inpatient diagnosis of primary 
cancer in a secondary position.
A means of identifying progression to metastatic cancer in 
claims data would make it possible to conduct claims based 
oncology research taking this critical outcome into account. 
Using information from patient charts linked to medical and 
pharmacy claims data, the present study sought simple algo-
rithms that could accurately identify cancer progression to 
metastatic disease in claims data alone. Separate algorithms 
were developed for three of the most common tumor types in 
the database.
MaTerials anD MeThODs
Data sources
The Geisinger Health System includes a single-state 700+ multi-
specialty physician group practice, 3 hospitals, 40 ambulatory 
clinics, a clinical reference laboratory, a non-exclusive health 
plan, and 3 dedicated research centers. The electronic health 
record (EHR) data include inpatient and outpatient care, as well as 
laboratory results, vital signs, and lifestyle data, including smok-
ing status. A cancer registry database includes clinical details, 
such as tumor size, grade, stage, and antineoplastic treatments. 
The cancer registry data, with supplemental manual review of 
inpatient and outpatient charts to confirm stage at diagnosis and 
occurrence or non-occurrence of cancer progression, provided 
the reference standard data for this analysis.
Claims data were obtained from the Geisinger Health Plan, 
which provides coverage for a subset of patients seen in the 
Geisinger Health System. The claims database covers all covered 
services from all sites of care and contains the usual data found in 
a claims database (e.g., enrollment dates, diagnosis and procedure 
codes, and pharmacy-dispensed medications).
Because the study involved only de-identified, retrospective 
data, it was exempt from IRB approval, and informed consent of 
patients was not required.
Patient selection
Patients were required to meet all of the following inclusion 
criteria:
• An initial diagnosis in the cancer registry of one of the fol-
lowing primary cancer types between January 1, 2004 and 
December 31, 2011, with stage at diagnosis indicated as I, II, 
or III:
 ° Breast [females only; International Classification of Dis-
eases for Oncology, Third Edition (ICD-O-3) code C50.x]
 ° Non-small cell lung cancer (NSCLC; C34.x, C33.9)
 ° Colorectal (C18.x, C19.9, C20.9, C21.0–C21.2, C21.8)
• Adults (≥18 years of age at date of initial cancer diagnosis)
• Enrolled in the Geisinger Health Plan at the time of initial 
diagnosis with cancer.
The date of initial cancer diagnosis was designated as the index 
date. Patients with a second primary tumor type on or before the 
index date, those whose continuous enrollment ended fewer than 
90 days after the index date, and those diagnosed with metastatic 
cancer before or within 60 days after the index date (i.e., during 
the initial workup for cancer) were excluded.
Outcome Definition
The study outcome was cancer progression to distant metastasis, 
defined as a cancer that has spread from the primary site to distant 
Abbreviations: EHR, electronic health record; ICD-9, International Classification 
of Diseases, ninth revision; ICD-O-3, International Classification of Diseases for 
Oncology, 3rd edition; IQR, interquartile range; NPV, negative predictive value; 
NSCLC, non-small cell lung cancer; PPV, positive predictive value; RF, random 
forests; SEER, surveillance, epidemiology, and end results.
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tissues or organs or to distant lymph nodes (15). To ascertain the 
outcome, medical record review was conducted for all patients 
enrolled in the study cohort. Inpatient and outpatient charts were 
reviewed, with particular emphasis on radiology, surgery, and 
pathology reports. The following data elements were extracted:
• Primary tumor site
• Diagnosis of metastatic (stage IV) cancer
• Date of diagnosis of stage IV cancer
• Locations of metastases
• Diagnostic methods used to diagnose metastases
• Any applicable supporting notes on metastasis diagnosis.
Research nurses who were trained in oncology extracted 
the clinical information using a standardized extraction form. 
De-identified data from completed abstraction forms were 
entered into the research database using a unique ID number for 
each patient.
Variable Definitions
Patients were followed through the claims data from the index 
date to the earliest of death, disenrollment from the health plan, 
or end of the study period to create variables considered for the 
claims algorithm. An initial algorithm was constructed with 
guidance from an oncologist. This initial algorithm specified 
the presence of at least one radiological or pathological claim 
≥60 days after the index date followed by at least one element 
derived from procedures, diagnoses, and medications that could 
indicate tumor progression to distant metastatic cancer. Indicator 
variables for drugs, diagnoses, and procedures were created with 
separate sets of variables for breast, lung, and CRC.
The variables included in the initial algorithm were events that 
occurred within 30  days after a radiology or pathology claim, 
where the radiology/pathology claim was required to occur at 
least 60 days after the index date; sensitivity analyses extended 
this time window to 90, 120, 180, and 365 days. The following 
variables were created:
• Diagnosis of secondary malignancy
• Diagnosis of a primary malignancy at a different site from the 
original tumor (malignancy of the contralateral breast or lung 
did not qualify as a different site)
• Another radiological procedure at a different site than the 
primary tumor
• Biopsy of site other than the primary tumor site
• Surgery for tumor excision at a new site or second surgery at 
the same site
• Use of pain medication (opioids)
• Use of medications for bone disease (e.g., bisphosphonates)
• Use of systemic corticosteroids
• Ambulatory aids (e.g., wheelchair)
• Airway management, for lung cancer only
• Feeding (parenteral nutrition), for lung cancer only
• Radiation therapy (with or without prior radiation therapy)
• Initiation of radiation therapy for patients with no prior his-
tory of this treatment
• Initiation of hormonal therapy, for breast cancer only
• Initiation of immunotherapy, for breast cancer only
• Change in chemotherapy from prior regimen
• Initiation of metastatic cancer-specific therapy
• Change from a multidrug regimen to a single antineoplastic 
agent
• Various diagnoses related to pain, confusion, seizures, or frac-
tures, or (for breast cancer only) a lump/swelling or shortness 
of breath.
statistical analysis
A separate algorithm consisting of a radiology or pathology claim 
followed by one or more of the variables listed previously was 
developed for each tumor type, with the cancer progression data 
obtained via chart review serving as the reference standard. The 
algorithm was developed through a hybrid clinical and empirical 
approach. Clinical insight drove each step of the process, with 
statistical methods used to test and refine the algorithm.
We first used random forests (RF) to evaluate the relative 
importance of variables in order to reduce a large set of potential 
predictor variables to a more parsimonious subset (16, 17). RF is 
a machine learning technique that grows a forest of decision trees, 
aggregates them, and yields a predicted status of metastatic or non-
metastatic cancer for each patient. RF incorporates randomness 
by sampling patients and variables to build the decision trees. The 
prediction accuracy of a tree is tested by classifying patients who 
were not used to build a tree and computing the misclassification 
rate. RF uses a permutation strategy to rank the importance of a 
variable to the prediction by measuring the decrease in prediction 
accuracy when the values of that variable are randomly permuted 
(18). The greater the loss of accuracy (i.e., more mismatches of 
patients as progressed or not progressed), the more important 
the variable is to the prediction. Because there are many more 
non-metastatic than metastatic patients, we pre-balanced the 
group sizes for each forest by randomly sampling from the larger 
group. Then, we ran 100 forests, using a new random selection of 
the non-metastatic patients each time, and averaged the results. 
Each forest had 1000 trees.
Using the variable importance results for each tumor type 
and each time window for the minimum time to the qualifying 
radiology/pathology claims, and applying clinical judgment to 
the combinations of variables with high importance, we selected a 
small number of predictor sets for each tumor type. One predictor 
set consisted of a single variable, which was established a priori 
as the ICD-9 code for secondary malignancy (i.e., metastasis); 
others included just two or three variables.
The single-variable model was evaluated using a simple 2 × 2 
table and associated performance measures, including sensitiv-
ity, specificity, PPV, and negative predictive value (NPV) (19). 
Two- or three-variable models were each used in a preliminary 
RF run to identify the forest error rates based on this small set 
of variables, and to look for highly predictive trees. To identify 
such trees, the preliminary forest was saved, and the 1000 saved 
decision trees from the forest were used in a second RF run, in 
which the trees were the predictor “variables.” This is called a 
synthetic forest (20); it is a way of evaluating the 1000 branching 
algorithms from the preliminary forest. The importance rankings 
TaBle 1 | Patient characteristics.
Patient 
characteristic at 
index date
Breast cancer 
(N = 502)
non-small cell 
lung cancer 
(N = 236)
colorectal 
cancer (N = 279)
age at index (years)
Mean (SD) 61.4 (13.3) 70.7 (9.3) 68.5 (12.5)
Median (range) 62 (30–89) 72 (43–89) 71 (23–89)
gender
Male 0 (0.0%) 134 (56.8%) 145 (52.0%)
Female 502 (100.0%) 102 (43.2%) 134 (48.0%)
ethnicity/race
White, not Hispanic 494 (98.4%) 234 (99.2%) 278 (99.6%)
Other 7 (1.4%) 2 (0.8%) 1 (0.4%)
Missing 1 (0.2%) 0 (0.0%) 0 (0.0%)
smoking status at index
Current/former 158 (31.5%) 180 (76.3%) 114 (40.9%)
Never 256 (51.0%) 14 (5.9%) 103 (36.9%)
Missing 88 (17.5%) 42 (17.8%) 62 (22.2%)
All cells are n (%) unless otherwise specified.
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of the trees enabled the identification of branching algorithms 
that performed consistently well. Since the saved forest only 
used a random sample of the larger (non-metastatic) group, 
this procedure was run multiple times. Forests with error rates 
widely different from the preliminary run were not considered. 
Of all algorithms tested, those that ranked consistently highly 
(i.e., those with the lowest error rates) were selected for further 
review.
The selected algorithms were applied to the full data set, and 
performance measures were calculated for each of the resulting 
2 ×  2 tables. Data management and initial analyses were per-
formed in SAS version 9.4 (21). The RF procedure was conducted 
in R version 3.3.1 (22) with the randomForests package version 
4.6-10 (23).
resUlTs anD DiscUssiOn
A total of 1357 patients were diagnosed with breast, NSCLC, or 
CRC from January 1, 2004 to December 31, 2011. After applying 
all inclusion and exclusion criteria, 1017 patients were eligible for 
the analysis, of whom 502 were diagnosed with breast cancer, 236 
with NSCLC, and 279 with CRC.
The median and interquartile range (IQR) of age of patients 
were 62 (51–72) years for breast cancer, 72 (65–78) years for 
NSCLC, and 71 (61–78) for CRC (Table 1). While all included 
patients with breast cancer were women, men composed of the 
majority of patients diagnosed with NSCLC (56.8%) and CRC 
(52.0%). Over 98% of patients with all tumor types were non-
Hispanic whites. NSCLC patients were more likely have a record 
indicating current or former smoking (76.3%) when compared to 
those with breast (31.5%) or CRC (40.9%), although nearly 20% 
of patients were missing data on smoking status. Median (IQR) 
follow-up enrollment in the Geisinger Health Plan, in months 
after the index date, was 35.7 (20.0–59.9) for breast cancer, 17.6 
(8.6–33.1) for lung cancer, and 30.7 (16.5–53.4) for CRC.
Progression algorithms
Breast Cancer
Only 17 of the breast cancer patients (3.4%) progressed to meta-
static cancer. Nearly all patients, including all of the patients who 
progressed, had a radiology or pathology claim ≥60 days after 
their initial cancer diagnosis (Table 2). Within 30 days following 
a qualifying radiology/pathology claim, a diagnosis of secondary 
malignancy, diagnosis of a second primary tumor, and initiation 
of immunotherapy appeared to discriminate most clearly between 
patients with and without progression to stage IV disease. The RF 
results supported this, with variable importance values that were 
highest for these three indicators.
First, an algorithm consisting of only the indicator for a 
secondary malignancy (i.e., the most appropriate coding of 
metastatic cancer using ICD-9 codes) was assessed (Figure 1). 
This algorithm had a sensitivity of 64.7% and specificity of 86.0%. 
Because of the very low incidence of progression to stage IV 
disease in breast cancer, the PPV was low, at 13.9%, with much 
higher NPV (98.6%).
Adding the variable for a second primary tumor at a different 
site from the breast to the secondary malignancy diagnosis, so 
that patients with either of these indicators were classified as 
having progressed, decreased the performance of the algorithm 
on all measures relative to the algorithm consisting of the sec-
ondary malignancy code alone. A more successful algorithm 
required the secondary malignancy diagnosis to be combined 
with either a malignancy at another site or initiation of immu-
notherapy. This last model obtained higher PPV (28.6%) and 
specificity (95.9%) but lower sensitivity (47.1%) than the model 
with secondary malignancy alone.
Sensitivity analyses delaying the start of the time window for 
qualifying radiology/pathology claims and subsequent elements 
obtained somewhat higher specificity and PPV than the 60-day 
results, but at the expense of some sensitivity. These analyses also 
required the exclusion of patients who progressed or were lost to 
follow-up within a year after the initial diagnosis.
Non-Small Cell Lung Cancer
Progression to stage IV cancer was more common in NSCLC 
than breast cancer, with 61 (25.8%) of patients having this out-
come. Again, nearly all patients with NSCLC had a radiology 
or pathology claim at ≥60 days after the index date (Table 2). 
The differences between patients who progressed and those 
who did not were not as consistent as with the breast cancer 
patients, although many variables showed sizeable differences, 
including secondary malignancy diagnosis, malignancy at a 
different site, use of pain medication, initiation of radiation 
therapy, change in chemotherapy regimen, and initiation of 
a metastatic-specific therapy. The variable importance values 
obtained from RF supported the use of secondary malignancy 
diagnosis, malignancy at a different site, and change in chemo-
therapy regimen.
The algorithm using only secondary malignancy performed 
better than the same model for breast cancer with respect to PPV 
(47.4%) but slightly worse on each of the other performance 
metrics (Figure 2). Adding malignancy at a different site identi-
fied no additional true positives and misclassified an additional 
TaBle 2 | Variables considered for cancer progression algorithm.
Breast cancer (N = 502) non-small cell lung cancer (N = 236) colorectal cancer (N = 279)Presence of characteristic for 
progression algorithm
Did not progress 
to stage iV 
(N = 485)
Progressed  
to stage iV 
(N = 17)
Did not progress 
to stage iV 
(N = 175)
Progressed  
to stage iV 
(N = 61)
Did not progress 
to stage iV 
(N = 246)
Progressed  
to stage iV 
(N = 33)
initial element, required within 30 days before each of the following elements
Radiological or pathological claim 
≥60 days after index day
481 (99.2%) 17 (100.0%) 171 (97.7%) 61 (100.0%) 236 (95.9%) 33 (100.0%)
additional elements following radiology/pathology claim
Secondary malignancy 68 (14.0%) 16 (94.1%) 41 (23.4%) 53 (86.9%) 18 (7.3%) 28 (84.8%)
Malignancy at different site 55 (11.3%) 12 (70.6%) 35 (20.0%) 36 (59.0%) 35 (14.2%) 19 (57.6%)
Another radiological procedure from  
non-primary tumor site
387 (79.8%) 17 (100.0%) 157 (89.7%) 60 (98.4%) 175 (71.1%) 32 (97.0%)
Biopsy claim from non-primary tumor 
site
77 (15.9%) 10 (58.8%) 27 (15.4%) 15 (24.6%) 29 (11.8%) 19 (57.6%)
More invasive surgery 26 (5.4%) 1 (5.9%) 2 (1.1%) 0 (0.0%) 30 (12.2%) 4 (12.1%)
Surgery on non-primary site 67 (13.8%) 3 (17.6%) 11 (6.3%) 6 (9.8%) 8 (3.3%) 7 (21.2%)
Pain medication 250 (51.5%) 10 (58.8%) 88 (50.3%) 47 (77.0%) 113 (45.9%) 21 (63.6%)
Medication for bone disease and bone 
pain
60 (12.4%) 2 (11.8%) 0 (0.0%) 5 (8.2%) 2 (0.8%) 0 (0.0%)
Corticosteroids 284 (58.6%) 15 (88.2%) 110 (62.9%) 51 (83.6%) 89 (36.2%) 22 (66.7%)
Wheelchair/aids for walking assistance 39 (8.0%) 4 (23.5%) 24 (13.7%) 16 (26.2%) 23 (9.3%) 5 (15.2%)
Radiation therapy (any) 358 (73.8%) 14 (82.4%) 74 (42.3%) 43 (70.5%) 42 (17.1%) 19 (57.6%)
Airway management N/A N/A 3 (1.7%) 5 (8.2%) N/A N/A
Feeding N/A N/A 1 (0.6%) 0 (0.0%) N/A N/A
Initiation of radiation therapy 138 (28.5%) 9 (52.9%) 26 (14.9%) 26 (42.6%) 12 (4.9%) 12 (36.4%)
Initiation of hormonal therapy 189 (39.0%) 4 (23.5%) N/A N/A N/A N/A
Initiation of immunotherapy 28 (5.8%) 8 (47.1%) N/A N/A N/A N/A
Change in chemotherapy 154 (31.8%) 12 (70.6%) 61 (34.9%) 38 (62.3%) 56 (22.8%) 29 (87.9%)
Initiation of metastatic-specific therapy 93 (19.2%) 8 (47.1%) 14 (8.0%) 16 (26.2%) 8 (3.3%) 20 (60.6%)
Change from multidrug regimen to 
single antineoplastic agent
36 (7.4%) 6 (35.3%) 5 (2.9%) 8 (13.1%) N/A N/A
Bone pain 54 (11.1%) 2 (11.8%) 12 (6.9%) 12 (19.7%) 10 (4.1%) 4 (12.1%)
Specific (non-bone) pain 128 (26.4%) 9 (52.9%) N/A N/A N/A N/A
Other pain 5 (1.0%) 1 (5.9%) N/A N/A N/A N/A
Confusion 0 (0.0%) 0 (0.0%) 1 (0.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Seizures 0 (0.0%) 0 (0.0%) 2 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Fractures 41 (8.5%) 1 (5.9%) 13 (7.4%) 7 (11.5%) 31 (12.6%) 1 (3.0%)
Lump/mass/swelling 21 (4.3%) 2 (11.8%) N/A N/A N/A N/A
Shortness of breath 64 (13.2%) 5 (29.4%) N/A N/A N/A N/A
All cells are n (%).
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15 patients who did not progress, leading to poorer performance 
on all measures except sensitivity. A more complex model, which 
classified patients as having progressed if they had a secondary 
malignancy diagnosis or a malignancy at a different site plus a 
change in chemotherapy, performed about the same as the model 
with secondary malignancy alone. For lung cancer, the sensitivity 
analysis requiring longer delays prior to the earliest qualifying 
radiology/pathology claims led to consistently higher error rates, 
and so models using those other time windows were not explored.
Colorectal Cancer
Among patients with CRC, 33 (11.8%) progressed to metastatic 
cancer, all of whom had a radiology or pathology claim at least 
60  days after initial diagnosis (Table  2). The secondary malig-
nancy diagnosis was again prominent among those who pro-
gressed, with other variables appearing to discriminate including 
malignancy at a different site, biopsy or surgery of a different site, 
radiation therapy, change in chemotherapy regimen, and initia-
tion of metastatic-specific therapy. The RF procedure found that 
secondary malignancy diagnosis and change in chemotherapy 
were the only two variables of high importance.
The model using only secondary malignancy diagnosis had 
good specificity (92.7%) and NPV (92.3%) but low sensitivity 
(42.4%) and PPV (43.8%; Figure 3). A model classifying patients 
with either a secondary malignancy or a change in chemotherapy 
had slightly better sensitivity but poorer performance on the other 
metrics. The sensitivity analysis requiring longer delays prior to 
the radiology/pathology claims had slightly lower error rates. 
Using a window of ≥120 days with the second model (secondary 
malignancy or change in chemotherapy), the PPV increased to 
34.0% and specificity to 87.3%, with values for sensitivity (50.0%) 
and NPV (93.0%) that were similar to the 60-day model.
FigUre 1 | Three algorithms for identifying progression to metastatic cancer among breast cancer patients. In each decision tree, “yes” responses are 
to the left and “no” to the right. Model 1 is the presence of an ICD-9 code for secondary malignancy. Model 2 includes secondary malignancy or a code for 
malignancy at a different site than breast as indicators of progression. For Model 3, secondary malignancy diagnosis plus either a malignancy at another site or 
initiation of immunotherapy indicate progression.
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Discussion
Progression in the stage of cancer may be an important early 
indicator of the effectiveness or lack of effectiveness of oncology 
therapy. Algorithms allowing identification of this outcome in 
routinely collected data would add significantly to our ability 
to conduct effectiveness and/or safety research in oncology. 
The present study utilized a hybrid clinical-empirical approach 
to develop algorithms for identifying progression to metastatic 
cancer in claims data. The performance of the algorithms was 
suboptimal, limiting their usefulness in future research, but the 
methods and findings may provide valuable guidance for further 
investigation into cancer progression.
In the ICD-9 coding scheme, metastatic cancer should be 
indicated by a secondary malignancy diagnosis code (197–199). 
Logically, the first occurrence of such a code should correspond to 
the date when progression to stage IV cancer was first identified. 
The present findings, however, demonstrate the serious impreci-
sion of this approach. Taking a time window for first occurrence 
of a secondary malignancy code of 90 days before to 90 days after 
the actual date of progression, 65% or fewer progression events 
were successfully identified. At the same time, many patients who 
did not progress were incorrectly identified as having progressed.
Through the additional consideration of many variables 
deemed to have high clinical relevance to the identification of 
cancer progression, and using validation via a robust statistical 
method that is able to maximize the use of limited datasets, more 
complex algorithms were built. Diagnosis codes for a second pri-
mary tumor at a different site than the original malignancy were 
frequently seen in the claims data for patients who progressed. 
The RF procedure found a high variable importance for this 
indicator for two of the three tumor types (breast and NSCLC). 
Some clinical coders may be entering metastatic sites using the 
primary rather than secondary malignancy codes, although 
adding this code to the progression algorithms added too many 
false positives to be useful. Still, considering the relative rarity of 
multiple primary tumors of different sites (24), any patient with 
claims for more than one primary tumor type should at least 
be considered a possible case of metastatic cancer. Changes in 
antineoplastic treatment regimens can serve as additional flags 
for possible metastatic cancer status.
The RF procedure inherently uses cross-validation as it tests 
the accuracy of each tree by calculating the accuracy using the 
patients not used to build the tree. This allowed us to more 
efficiently use our small sample for both training and valida-
tion. In addition, the group sizes were pre-balanced prior to 
running each forest, which is a form of cross-validation. The 
initial analysis results consisted of the average performance 
over 100 such forests. Nevertheless, the number of patients 
FigUre 2 | Three algorithms for identifying progression to metastatic cancer among nsclc patients. Model 1 is the presence of an ICD-9 code for 
secondary malignancy. In Model 2, secondary malignancy or a code for malignancy at a different site than lung indicate progression. Model 3 includes either 
secondary malignancy diagnosis or a malignancy at a different site plus a change in chemotherapy as markers of progression.
FigUre 3 | Two algorithms for identifying progression to metastatic cancer among colorectal cancer patients. Model 1 is the presence of an ICD-9 code 
for secondary malignancy. Model 2 classifies patients as progressed if they have either a secondary malignancy code or a change in chemotherapy regimen.
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who progressed, especially in the breast cancer cohort, was low 
enough to limit the usefulness of any algorithm developed in 
this study. In addition, the specificity and NPV of the algorithms 
is relatively uninformative, given the low proportion of patients 
who progressed; interpretation of the results should focus on the 
PPV and sensitivity.
Other limitations include the potential for missing data, in 
both the cancer registry and claims data sources. Diagnoses of 
stage IV cancer that occurred outside of the Geisinger Health 
System would be missing from the cancer registry and chart 
review. Missing claims data can lead to failure to identify pat-
terns in claims that would more accurately distinguish between 
metastatic and earlier stage cancer. Treatment, diagnoses, 
and procedures that occurred but were not included in claims 
because they did not lead to billable medical care or were covered 
by dual insurance could not be identified as missing and were 
assumed not to have occurred. With the knowledge that claims 
data are imperfect, this study was performed to assess whether 
claims-based algorithms can be created to identify progression 
to metastatic cancer.
A minimum of 3  months of follow-up was required for 
patients to identify cancer progression to metastatic cancer. The 
results thus may not reflect the patterns of care for patients who 
died or disenrolled from the health plan shortly after initial 
diagnosis. The study population was derived from a single-state 
health plan and health system and may not be generalizable 
to the United States population. The reference standard used 
in this study was based on a manual chart review, which is an 
excellent source of information but still imperfect, especially 
considering the complexities of cancer staging and the poten-
tial for missing progression events that occurred. The overall 
rate of progression was lower than expected, which may have 
resulted from patients with advanced cancer seeking care from 
an oncology specialty center outside of the Geisinger system, 
or from progression events that were missed during the chart 
review.
It is possible that better-performing algorithms could have 
been developed using different machine learning techniques or 
by creating more empirically driven variables, identified through 
an exhaustive search of all claims for patients who progressed and 
those who did not. Still, an empirically based algorithm that lacks 
the clinical perspective offered in our present efforts may suffer 
from poor clinical validity as well as weighing too heavily the 
idiosyncrasies of the patient data included in the study sample.
cOnclUsiOn
The results of this study suggest that identification of progres-
sion to distant metastatic cancer is not likely to be valid using 
claims data alone. There are limitations to each of the informa-
tion sources that jeopardize the development of a consistently 
high-performing algorithm. Additional information, derived 
from medical records or cancer registries, is needed for accurate 
ascertainment of this outcome.
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